Recombinant interferon‐α therapy in patients with follicular lymphoma

Advanced stage, follicular, non‐Hodgkin's lymphoma (NHL) has no cure and no single standard of care. Remissions induced by standard chemotherapy regimens generally are not durable and, with the exception of selected patients with limited early stage disease, most patients with follicular NHL eventually die of their disease. Recombinant interferon‐α (rIFN‐α) has demonstrated activity against follicular NHL in clinical trials.

[1]  R. Gelber,et al.  Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Tilly,et al.  Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  W Hiddemann,et al.  Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. , 1996, Leukemia.

[4]  H. Tilly,et al.  Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Avilés,et al.  Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. , 1996, Leukemia & lymphoma.

[6]  W. Hiddemann,et al.  New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only--a preliminary update of the German Low-Grade Lymphoma Study Group. , 1994, Seminars in hematology.

[7]  J. Andersen,et al.  Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: five-year follow-up. , 1993, The New England journal of medicine.

[8]  B. Coiffier,et al.  Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. , 1993, The New England journal of medicine.

[9]  S. Horning.  Natural history of and therapy for the indolent non-Hodgkin's lymphomas. , 1993, Seminars in oncology.

[10]  B. Nathwani,et al.  Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B. Coiffier.  Interferon alpha-recombinant in the treatment of follicular lymphoma patients. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  W. Velasquez,et al.  CHOP-Bleo plus interferon for stage IV low-grade lymphoma. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M. Oken,et al.  Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. , 1992, The New England journal of medicine.

[14]  S. Korsmeyer.  Bcl-2 initiates a new category of oncogenes: regulators of cell death. , 1992, Blood.

[15]  W. Velasquez,et al.  Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Berger,et al.  Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  T. Lister,et al.  Interferon-alpha 2b in the treatment of follicular lymphoma: preliminary results of a trial in progress. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  R. Gelber,et al.  Quality adjusted survival analysis. , 1990, Statistics in medicine.

[19]  S. Wadler,et al.  Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. , 1990, Cancer research.

[20]  C. Portlock.  Management of the low-grade non-Hodgkin's lymphomas. , 1990, Seminars in oncology.

[21]  E. Jaffe,et al.  The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. , 1988, Seminars in hematology.

[22]  D. Deakin,et al.  Maintenance chlorambucil after CVP in the management of advanced stage, low‐grade histologic type non‐Hodgkin's lymphoma: A randomized prospective study with an assessment of prognostic factors , 1988, Cancer.

[23]  R. Kaplan,et al.  A randomized trial of high dose cyclophosphamide, vincristine, and prednisone plus or minus doxorubicin (CVP versus CAVP) with long-term follow-up in advanced non-Hodgkin's lymphoma. , 1987, Leukemia.

[24]  R. Spiegel,et al.  Alfa-2b interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma. , 1987, Seminars in oncology.

[25]  F. Cabanillas,et al.  Long‐term results of treatment of patients with follicular lymphomas , 1987, Hematological oncology.

[26]  T. Lister,et al.  Chlorambucil and interferon for low grade non-Hodgkin's lymphoma. , 1987, British Journal of Cancer.

[27]  T. Lister,et al.  Follicular lymphoma: prognostic factors for response and survival. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  B. Nathwani,et al.  What should be the morphologic criteria for the subdivision of follicular lymphomas , 1986 .

[29]  M. Oken,et al.  Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Kurzrock,et al.  Clinical toxicity of interferons in cancer patients: a review. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Y. Tsujimoto,et al.  Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.

[32]  J. Glick,et al.  Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  S. Horning,et al.  The natural history of initially untreated low-grade non-Hodgkin's lymphomas. , 1984, The New England journal of medicine.

[34]  D. Longo,et al.  Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. , 1984, The New England journal of medicine.

[35]  N. Harris,et al.  Immunohistologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies. Follicular and diffuse lymphomas of small-cleaved-cell type are related but distinct entities. , 1984, The American journal of pathology.

[36]  G. Pinkus,et al.  Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies. , 1984, Cancer treatment reports.

[37]  F. Balkwill,et al.  Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. , 1984, Cancer research.

[38]  P. Neiman,et al.  Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients. , 1983, Blood.

[39]  J. Glick,et al.  Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. , 1981, Blood.

[40]  C. Coltman,et al.  Superiority of adriamycin‐containing combination chemotherapy in the treatment of diffuse lymphoma. A southwest oncology group study , 1979, Cancer.

[41]  E. Kimby,et al.  Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[43]  T. Chisesi,et al.  The role of interferon alfa-2b and chlorambucil in the treatment of non-Hodgkin's lymphoma. , 1988, Cancer treatment reviews.

[44]  Bharat,et al.  What should be the morphologic criteria for the subdivision of follicular lymphomas? , 1986, Blood.

[45]  C C Whitcomb,et al.  Morphological subclassification of follicular lymphoma: variability of diagnoses among hematopathologists, a collaborative study between the Repository Center and Pathology Panel for Lymphoma Clinical Studies. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  I. Gresser,et al.  Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice. , 1978, European journal of cancer.